SLC5A2 and liver dysplastic nodule: Although recent advances emphasized the therapeutic value of sodium-dependent glucose transporters 2 (SGLT2) (Zelniker et al., 2019), inhibitors, and glucagon-like peptide 1 (GLP-1) (Kristensen et al., 2019) receptor agonist for DN and developing novel anti-diabetic agents that have facilitated optimum glycemic control, DN has not yet been cured, indicating the need for cause-specific treatments.